Navigation Links
Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
Date:5/8/2013

SAN DIEGO, May 8, 2013 /PRNewswire/ -- Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases, announced today that it will present analysis methods for  the MYDICAR development program at an upcoming Conference.

The conference "Statisticians in the Pharmaceutical Industry International Conference" is being held in Glasgow, UK, on 12-15 May, 2013

  • "Analysis of Recurrent Heart Failure Hospitalizations in Presence of Informative Censoring" – Application of Joint Frailty Model  by Alex Yaroshinsky (Celladon Corporation); Ladislav Pecen (SIRO Clinpharm); and Alena Cernikova (SIRO Clinpharm)

"This conference presentation represents additional recognition of Celladon's innovative approach to the MYDICAR development program, and has many benefits over traditional analysis methods including reduced sample size relative to other heart failure trials," said Krisztina Zsebo Ph.D., President and CEO of Celladon Corp.  "It is the first time the U.S Food and Drug Administration has accepted the use of this statistical analysis method as part of a primary endpoint in a clinical trial for the treatment of heart failure," continued Dr. Zsebo.

About MYDICAR

MYDICAR is a genetically targeted enzyme replacement therapy intended to restore levels of SERCA2a, a regulator of calcium cycling in the heart and cardiac contractility. SERCA2a levels decline in all forms of late-stage HF resulting in deficient heart function. With MYDICAR, the SERCA2a gene is delivered using recombinant adeno-associated virus (AAV) as the vector. AAV is a naturally occurring virus not associated with any disease in humans. MYDICAR is delivered in a single dose directly to the heart during a
'/>"/>

SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
2. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
3. ETEX Corporation announces extended Supply Agreement with Knee Creations, LLC
4. Verenium Corporation to Announce First Quarter 2013 Financial Results
5. EMCO High Voltage Corporation to Exhibit at 61st ASMS Conference on Mass Spectrometry and Allied Topics
6. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
7. Celsion Corporation to Hold First Quarter 2013 Financial Results Conference Call on Thursday, May 9, 2013
8. Techne Corporation Releases Unaudited Third Quarter And Nine Month Fiscal Year 2013 Results
9. Street Named After EMCO High Voltage Corporation
10. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
11. Celsion Corporation Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 2015  MiMedx Group, Inc. (NASDAQ: MDXG ), ... and patent-protected processes to develop and market advanced products ... Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced ... Annual Canaccord|Genuity Growth Conference in Boston, ... CEO, William C. Taylor , President and COO, ...
(Date:8/3/2015)... -- Merck KGaA, Darmstadt, Germany ,  a ... the healthcare, life science and performance materials sectors, announced ... and launch of promising new fullerene derivatives for the ... Germany , is pursuing many projects ... Novel derivatives: highly stable, easy to process and cost ...
(Date:8/3/2015)... 2015  Aethlon Medical, Inc. (Nasdaq: AEMD ), ... life-threatening diseases, today announced that it will host its ... on Thursday, August 13, 2015 at 4:30 p.m. Eastern ... the release of fiscal 2016 first quarter results.  A ... two hours after the call at the Investor Relations ...
(Date:8/3/2015)... Aug. 3, 2015   Intrexon Corporation (NYSE: ... half and second quarter 2015 financial results after the ... The Company will host a conference call at 5:30 ... general business update. The conference call may ... (International), and asking to join the "Intrexon Corporation Call."  ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Aethlon Medical To Host First Quarter Fiscal 2016 Investor Call on August 13, 2015 2Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2
... 2011 Reportlinker.com announces that a ... in its catalogue: What,s ... and Other Biologics) 2011-2015 ... future of the pharmaceutical market will ...
... aid the fight of the deadly outbreak of E. ... at the University Medical Centre Hamburg-Eppendorf have released an ... data previously released and submitted to NCBI in the ... assembled using the latest ion semiconductor sequencing technology, there ...
... Asmacure Ltee, a clinical-stage biopharmaceutical company focused ... treatment of asthma and other inflammatory diseases, announced today ... officer.  With a solid foundation established at Asmacure, Mr. ... lead compound, a potential new treatment for asthma with ...
Cached Biology Technology:Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 2Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 3Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 4Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 5Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 6Reportlinker Adds What's Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015 7Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 2Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics 3Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
(Date:7/21/2015)... Connecticut , July 21, 2015  NXT-ID, ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet, announces that it has filed ... System and Method. This invention ... not only authorizes an account, but also the ...
(Date:7/13/2015)... Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION METHOD ... convenient and secure method to make payments.  With ... methods, introduced with its groundbreaking voice-direct payment patent ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... to hear relies on hair cells, sensory receptors that mechanically ... transduction channel. Although the transduction channel was characterized more than ... molecular components. A new study in The Journal ... definitive identification of this mystery channel. Recent studies ...
... a long and complex process. Candidate drugs are evaluated ... of animals, usually rats or mice. Each class of ... often in a labor-intensive process that leaves plenty of ... consensus that current procedures fail to effectively produce new ...
... Clinical Practice Guideline (CPG) for the diagnosis and treatment ... in women of reproductive age and a leading cause ... of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice ... the Journal of Clinical Endocrinology and Metabolism ...
Cached Biology News:Finding psychiatric drugs in the movements of mice 2Finding psychiatric drugs in the movements of mice 3Experts clarify conflicting criteria for diagnosing polycystic ovary syndrome 2
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
Biology Products: